natgillin/translations-raw huggingface dataset:
Suitable adjuvants include, but are not limited to, 1018 ISS, aluminum salts, Amplivax, AS 15, BCG, CP-870,893, CpG7909, CyaA, dSLIM, flagellin or TLR5 ligands derived from flagellin, FLT3 ligand, GM-CSF, IC30, IC31, Imiquimod (ALDARA), resimiquimod, ImuFact IMP321, Interleukins as IL-2, IL-13, IL-21, Interferon-alpha or -beta, pegylated derivations thereof, IS Patch, ISS, ISCOMATRIX, ISCOMs, JuvImmune, LipoVac, MALP2, MF59, monophosphoryl lipid A, Montanide IMS 1312, Montanide ISA 206, Montanide ISA 50V, Montanide ISA-51, water-in-oil and oil-in-water emulsions, OK-432, OM-174, OM-197-MP-EC, ONTAK, OspA, PepTel® vector system, PLG and dextran microparticles, resiquimod, SRL172, Virosomes and other Virus-like particles, YF-17D, VEGF trap, R848, beta-glucan, Pam3Cys, Aquila's QS21 stimulon, which is derived from saponin, mycobacterial extracts and synthetic bacterial cell wall mimics, and other proprietary adjuvants such as Ribi's Detox, Quil, or Superfos. 
Farmaceutski sastav prema zahtjevu 1 ili 2, gdje najmanje jedan peptid uključuje nepeptidne veze. Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 3, gdje je odabir, broj i/ili količina peptida prisutnih u sastavu specifičan za tkivo, karcinom i/ili pacijenta. Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 4, koji nadalje uključuje najmanje jedan prikladan adjuvans odabran iz skupine koja sadrži 1018 ISS, aluminijeve soli, Amplivax, AS15, BCG, CP-870,893, CpG7909, CyaA, dSLIM, GM-CSF, IC30, IC31, imikvimod, ImuFact IMP321, IS Patch, ISCOMATRIX, JuvImmune, LipoVac, MFS59, monofosforilni lipid A, Montanide IMS 1312, Montanide ISA 206, Montanide ISA 50V, Montanide ISA-51, OK-432, OM-174, OM-197-MP-EC, ONTAK, vektorski sustav PepTel, PLG mikro-čestice, resikvimod, SRL172, Virosomes 1 druge čestice slične virusima, YF-17DBCG, stimulon QS21 kompanije Aquila Biotech, Ribi's Detox.
or a pharmaceutically acceptable salt or acid addition salt, a racemic mixture, or its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. 
IE ili ili njegova farmaceutski prihvatljiva sol ili kiselinska adicijska sol, njegova racemična smjesa ili njezini odgovarajući enantiomer i/ili optički izomer i/ili stereoizomer.
The communication apparatus of claim 1, further comprising a client interface adapted to communicate data from the event/data recorder to a remote computer and to communicate commands from the remote computer to the EDR interface. The communication apparatus of claim 4, further adapted to: 
Komunikacijski uređaj sukladno zahtjevu 1, naznačen time, da nadalje obuhvaća korisničko sučelje (112) prilagođen za prijenos podataka s uređajem za snimanje događaja/podataka na bežični predajnik (115) 1 za izdavanje naredbi od udaljenog računala na EDR sučelje.
pyridyl optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-6 alkyl, or C1-6 haloalkyl; 
(1) piridil je po želji supstituiran sa 1, 2, ili 3 supstituenta nezavisno izabranih od halo, Cis alkila, ili Cig haloalkila;
if the compound of claim 1 prepared in step (a) or step (b) is a diacid, forming a mono- or diester of the compound; or 
(c) ako je spoj iz zahtjeva 1 pripravljen u koraku (a) ili koraku (b) dikiselina, nastaju mono- i di-cstcri spoja; ili
A is a Stretcher unit covalently attached to a cysteine thiol of the antibody (Ab); 
(i) protutijelo je kovalentno priključeno na zahvatnu oznaku, detekcijsku oznaku ili na kruti nosač, ili
In certain embodiments, the solid form further comprises peaks at approximately 17.65, 22.47, and 26.77 degrees 2θ. 
Čvrsti oblik prema zahtjevu 1, naznačen time što XRPD uzorak nadalje sadrži vrhove na približno 17.65, 22.47 i 26.77 stupnjeva 20.
The process according to claim 12 for the preparation of a compound of formula (III) in which both R and R' are a -CONH-CH2-CH(OH)CH2OH, R4 is methyl and R5 is hydrogen. 
Postupak u skladu s patentnim zahtjevom 12 za pripremu tvari formule (III) pri čemu su oboje R i R' –CONH-CH2-CH(OH)CH2OH, R4 je metil i R5 je vodik.
The peptide-derived molecule according to Embodiment 1 to 3 having the amino acid sequence of SEQ.ID NO.2. 
Molekula izvedena iz peptida prema zahtjevima 1 do 3, naznačena time da ima sekvencu aminokiselina koja se bira iz skupine koja se sastoji od:
The method of claim 7, wherein at least one flap of the second set of flaps extends from one of the sides of the upper face at a distance that is greater than half the length of the sides of the upper face which include the first set of flaps. A method for storing and shipping a box, comprising: 
Kutija za skladištenje i transport prema zahtjevu 1, koja sadrži veći broj ploha koje čine tijelo koje je u bitnome paralelepiped, gdje se najmanje jedan od navedenih drugih preklopa za zatvaranje (2) za skladištenje proteže s jedne od strana gornje plohe tog tijela na udaljenosti (12) koja je veća od polovice duljine (L1) drugih strana plohe koje uključuju prve preklope (1) za transport.
After 10 minutes, the reaction mixture is added to ice/water and extracted with EtOAc. 
Nakon 10 minuta, reakcijsku smjesu se doda u led/vodu i ekstrahira s EtOAc, Organski sloj se ispere sa zas.
The compound for use of claim 21, wherein the second therapeutic agent is an azole, a polyene, a purine or pyrimidine nucleotide inhibitor, a pneumocandin or echinocandin derivative, a protein elongation factor inhibitor, a chitin inhibitor, a mannan inhibitor, a bactericidal or permeability-inducing (BPI) protein product, or an immunomodulating agent. 
Spoj za uporabu prema patentnom zahtjevu 21, naznačen time, što je drugi terapeutski agens azol, polien, inhibitor purinskih ili pirimidinskih nukleotida, derivat pneumokandina ili ehinokandina, inhibitor elongacionog faktora proteina, inhibitor hitina, inhibitor manana, baktericidni ili proteinski proizvod koji inducira permeabilnost (BPI), ili imunomodulirajući agens.
and R4 together with the nitrogen group form an aliphatic amine. 
i R3 uzeti zajedno sa dušikovom grupom formiraju alifatični amin.
A filter as claimed in claim 1, in which the at least one deflector includes first and second deflectors which are provided within the inlet and outlet ports respectively. 
Filter (10) sukladno zahtjevu 1, pri čemu su prvi i drugi deflektori (100) pruženi unutar prvog i drugog ulaza (96).
The pharmaceutical composition in claim 8 wherein said one or more additional pharmaceutically active compounds are chosen from the group consisting of known anti-inflammatory agents. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 8, naznačen time što se navedeni jedan ili više dodatnih farmaceutski aktivnih spojeva bira iz skupine koju čine poznata protuupalna sredstva.
A method of controlling rust diseases on soybean plants, which comprises applying to the useful plants, the locus thereof or propagation material thereof a composition comprising a compound of formula (I) wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo. 
Pripravak koji je pogodan za nadzor bolesti uzrokovanih fitopatogenim organizmima uključujući (A) spoj formule I [image] naznačen time da je R1 difluorometil ili trifluorometil, a X kloro, fluoro, ili bromo; i (B) spoj klorotalonil.
Use according embodiment 8 or 9 characterised in that the fentanyl is given before administration of CNS 7056, preferably within 10 minutes, more preferably within 5 minutes, and most preferably within 1 or 2 minutes prior to CNS 7056 administration. 
CNS 7056 ili njegova sol ili solvat za primjenu sukladno bilo kojem od prethodnih zahtjeva, naznačen time što se fentanil daje prije davanja CNS 7056, a prvenstveno u roku od 10 minuta, još poželjnije u roku od 5 minuta, i najpoželjnije u roku od 1 ili 2 minuta prije davanja CNS 7056.
the onboard sentinel further comprises a data processor module that is capable of detecting a drop in fuel level at constant geographical position from successive stored rows of data and, if a drop in fuel level is detected at constant geographical position, i.e. 
- montirano kućište (10) dodatno sadrži modul za obradu podataka (104) koji je sposoban za otkrivanje pada razine goriva kod konstantnog geografskog položaja iz uzastopno pohranjenih redova podataka (Lpyu) i, ako je otkriven pad razine goriva kod konstantnog geografskog položaja, tj.
The compound of Claim 1, wherein R1A is an optionally substituted O-linked amino acid, or R1A is wherein R40A is selected from the group consisting of hydrogen, an optionally substituted C1-6 alkyl, an optionally substituted C1-6 haloalkyl, an optionally substituted C3-6 cycloalkyl, an optionally substituted C6 aryl, an optionally substituted C10 aryl and an optionally substituted aryl(C1-6 alkyl), and R41A is hydrogen or an optionally substituted C1-4 alkyl, or R40A and R41A are taken together to form an optionally substituted C3-6 cycloalkyl, preferably R40A is an optionally substituted C1-6 alkyl, preferably R40A is methyl, preferably R41A is hydrogen. 
Spoj prema zahtjevu 1, naznačen time što R1A je po izboru supstituirana O-vezana aminokiselina, ili R1A je pri čemu je R40A odabran iz skupine koju čine vodik, po izboru supstituiran C1-6 alkil, po izboru supstituiran C1-6 haloalkil, po izboru supstituiran C3-6 cikloalkil, po izboru supstituiran C6aril, po izboru supstituiran C10 aril i po izboru supstituiran aril(C1-6 alkil), i R41A je vodik ili po izboru supstituiran C1-4alkil, ili R40A i R41A su uzeti zajedno da tvore po izboru supstituiran C3-6 cikloalkil, poželjno R40A je po izboru supstituiran C1-6 alkil, poželjno R40A je metil, poželjno R41A je vodik.
The apparatus according to claim 46, wherein a filter belt covers at least a part of the surface of the pore roller, such as a filter belt surrounding the surface of the pore roller. 
Uređaj prema zahtjevu 11, naznačen time da filtarska traka pokriva barem dio površine valjka s porama, osobito filtarska traka koja obuhvaća površinu valjka s porama.
The cement admixture as recited in claim 3, wherein said calcium ferroaluminate and said potentially hydraulic substance and/or said pozzolan substance are blended together in a blending proportion of 10/1 to 1/10 by mass. 
Cementna primjesa u skladu s patentnim zahtjevom 3, naznačena time što se navedeni kalcijev feroaluminat i navedenu potencijalno hidrauličnu tvar i/ili navedenu pucolansku tvar pomiješa zajedno u omjeru miješanja od 10/1 do 1/10, maseno.
wherein the sealing member is pressed against the cooperating enclosing member to form a flow resistance which is effective to enable pressure in the capsule to rise sufficiently until the opening of the outlet face. 
- pri čemu je element za brtvljenje (8) potisnut na pripadajući element za obuhvaćanje čahure da bi se stvorio otpor za protok koji djeluje tako da se može dovoljno povećati tlak u čahuri, (1) sve dok se ne otvori izlazna ploha,
A printed product, comprising at least one coating layer, said at least one coating layer further comprising at least one type of magnetic optically variable pigment particles, characterized in that indicia are embodied in said at least one coating layer through a selective orientation of said magnetic optically variable pigment particles, as a result of an exposure of said coating layer to the magnetic field at the surface of the device according to claim 1 while said at least one coating layer is wet, followed by hardening said at least one coating layer. 
Tiskani proizvod, poželjno novčanica, vrijednosni papir, službeni dokument, porezna markica, etiketa, folija, nit ili naljepnica, koji sadrži najmanje jedan premaz, pri čemu navedeni premaz dodatno sadrži čestice najmanje jedne vrste magnetskog optički varijabilnog pigmenta, naznačen time, da su oznake uključene u navedeni premaz selektivnim usmjeravanjem navedenih čestica magnetskog optički varijabilnog pigmenta, kao posljedica izlaganju navedenog premaza djelovanju magnetskog polja na površini uređaja sukladno jednom ili više patentnih zahtjeva 1 do 6 za vrijeme dok je navedeni premaz vlažan, nakon čega slijedi otvrdnjavanje navedenog premaza.
Identification of microRNAs of the herpesvirus family. 
Broj objave europskog patenta:
The method of claim 13, wherein said patient medical record is maintained by a laboratory, physician's office, a hospital, a health maintenance organization, an insurance company, or a personal medical record website. 
Postupak prema patentnom zahtjevu 13, naznačen time što medicinsku dokumentaciju pacijenta vodi laboratorij, ured zaduženog liječnika, bolnica, zdravstvena organizacija, osiguravajuće društvo ili služba internet stranice za osobne zdravstvene kartone.
preventing, slowing, delaying or treating diseases or conditions attributed to an abnormal accumulation of liver fat; or 
- prevencija, usporavanje, odgađanje ili liječenje bolesti ili stanja, koja se pripisuju abnormalnoj akumulaciji masti u jetri; ili
wherein the biotic in (a), (b) and (c) is a probiotic selected from the list consisting of a species of Lactobacillus, Bifidobacterium, Escherichia, Saccharomyces, Streptococcus and Bacillus and, or a prebiotic which facilitates growth and maintenance of microflora in the subject or both. 
naznačen time da je probiotik u (a), (b), (c) izabran s liste koja se sastoji od vrsta Lactobacillus, Bifidobacterium, Escherichia, Saccharomyces, Streptococcus i Bacillus.
The crude imine was dissolved in methanol (50 ml. 
Sirovi imin se otopi u metanolu (50 ml.
Arrangement according to claim 5,characterized in that it further comprises a control arrangement for controlling the system when operating in liquid fuel and gaseous fuel modes, respectively, a controller (14) for controlling the pump (4) of gaseous fuel in liquid state when operating in gaseous fuel mode, a fuel controller (10) for controlling the system when operating in liquid fuel and gaseous fuel modes, respectively. 
Ustrojstvo u skladu sa zahtjevom 5, naznačeno time da nadalje sadrži upravljački uređaj za upravljanje sustavom tijekom rada u načinima rada tekućeg goriva i plinovitog goriva, odnosno, kontrolor (14) za upravljanje pumpom (4) plinovitog goriva u tekućoj fazi tijekom rada u načinu rada plinovitog goriva, kontrolor goriva (10) za upravljanje sustavom tijekom rada u načinima rada tekućeg goriva i plinovitog goriva, odnosno.
All dosing solutions of the compound of formula (2) were iso-osmotic (290+/−50 mOsm/kg). 
(e) najmanje 15 ug spoja sa formulama (1) ili (2)/kg/minuti.
Nonburning carbon or graphite fibers may be used in place of ceramic fibers. 
Umjesto keramičkih vlakana mogu se koristiti neizgoriva ugljična ili grafitna vlakna.
or the corresponding sodium or potassium salt of the formula V 
R2 ili odgovarajuće natrijeve ili kalijeve soli formule V o
The present invention provides a compound of formula Ib: 
PATENTNI ZAHTJEVI 1. Spoj s formulom Ib: a
The aerosol forming substance may be dispersed on or within the aerosol generating means in a concentration sufficient to permeate or coat the substrate, carrier, or container. 
Supstanca za formiranje aerosola može se dispergirati na ili unutar sredstva za generiranje aerosola u zadovoljavajućoj koncentraciji da prolazi kroz ili prevlaci supstrat, nosač ili kontejner.
A compound, wherein the compound is represented by the following structural formula: 
Spoj sukladno zahtjevu 1, naznačen time, da je spoj predstavljen slijedećom strukturnom formulom:
The process of claim 1, wherein the extractor is a tower with internals to promote mass transfer. 
Proces prema patentnom zahtjevu 9, naznačen time, da je ekstraktorska posuda (5) jedan toranj s unutarnjom opremom koja pospješuje transfer mase.
Use of an amount of an opioid antagonist in an amount at least sufficient to substantially antagonize a therapeutic amount of opioid agonist when both, the opioid agonist and the opioid antagonist, are administered intravenous at the same time, in the form of a controlled release dosage form comprising a homogeneous controlled release matrix formulation comprising a hydrophobic material, including at least one hydrophobic polymer, wherein the hydrophobic polymer is ethyl cellulose, and at least one fatty alcohol or fatty acid selected from C12 to C36 aliphatic alcohols or acids, and said therapeutic amount of an opioid agonist and said sufficient amount of opioid antagonist, to prevent the formation of an extract of said controlled release matrix formulation comprising the opioid agonist by a one step extraction procedure comprising the steps of: 
Uporaba količine opioidnog antagonista koja je dovoljna da barem bitno djeluje antagonistički na terapijsku količinu opioidnog agonista kada se oba, opioidni agonist i opioidni antagonist, daju istodobno intravenski kao dozirni oblik s kontroliranim oslobađanjem koji sadrži homogenu formulaciju matriksa s kontroliranim oslobađanjem, a koja sadrži hidrofobni materijal, uključujući barem jedan hidrofobni polimer, gdje je hidrofobni polimer etil celuloza i barem jedan masni alkohol ili masnu kiselinu izabrane između C12 do C36 alifatskih alkohola ili kiselina, i terapijsku količinu opioidnog agonista i dovoljnu količinu opioidnog antagonista, da se spriječi nastanak ekstrakta formulacije matriksa s kontroliranim oslobađanjem koja sadrži opioidni agonist pomoću postupka ekstrakcije u jednom koraku, a postupak obuhvaća korake:
A method for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound of claim 1 . 
Metoda za suzbijanje štetnog beskralješnjaka, naznačena time, što se sastoji od dovođenja u kontakt štetnog beskralježnjaka ili njegove okoline sa smjesom iz bilo kojeg od Zahtjeva 9 do 16, uz uvjet da metoda nije metoda liječenja čovjeka ili životinje putem terapije.
In such an embodiment having at least the plurality of scent module accommodations, optionally, the housing comprises a single air and scent perfume mixing chamber with more than one of the plurality of accommodations, and a valve between at least one of the plurality of accommodations and the single air and scent perfume mixing chamber. 
Sklop u skladu sa patentnim zahtjevom 6 ili 7, gdje navedeno kućište sadrži jednu komoru za miješanje zraka i mirisnog parfema sa više od jednog od navedenih više prijemnih dijelova, i ventil između najmanje jednog od navedenih više prijemnih dijelova i navedenu jednu komoru za miješanje zraka i mirisnog parfema.
A method for reducing or stopping bleeding in a patient suffering from uterine fibroids, the method comprising administering orally to the patient for at least one menstrual cycle a daily oral dosage ranging from about 5 mg to about 20 mg of 17a acetoxy-11B-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate), wherein bleeding is reduced or stopped after the administration of ulipristal acetate for one menstrual cycle. 
Ulipristal acetat (17a-acetoksi-115-[4-N,N-dimetilamino-fenil)-19-norpregna-4,9-dien-3,20-dion) ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 za daljnju uporabu u prevenciji ili liječenju anemije u te bolesnice,
The membranes are vortexed to resuspend the crude membrane pellet and homogenized with a Brinkmann PT-3100 Polytron homogenizer for 15 seconds at setting 6. 
Membrane su zatim zavrtložene da se resuspendira sirova peleta membrana i homogenizira se sa Brinkman PT-3100 Polytron homogenizatorom tijekom 15 sekundi na položaju 6.
up to about 2% lubricant, suitably up to about 1.5%, suitably up to about 1%; and 
€) Do oko 2% sredstva za podmazivanje (lubrikant); i 1) Od 4% do oko 12% sredstva za raspadanje.
said anti-HERV-W Env ligand is an antibody, more particularly a chimeric, engineered or humanized antibody, and even more particularly an IgG, such as an IgG1 or an IgG4, wherein said antibody comprises each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 
- navedeni anti-HERV-W Env ligand je antitijelo, točnije kimerno, projektirano ili humanizirano antitijelo, 1 još točnije IgG, poput IgG1 ili IgG4, pri čemu navedeno antitijelo sadrži svaku od regija koje određuju komplementarnost (CDR) navedenih u SEQ ID No.
wherein A3, X1, X2, L1, R1, R3 and n are as defined above and when L1 is nitro, said nitro group is reduced to an amino group and the amino derivative obtained is then reacted with a compound of formula III G-A4 b -L0 (III), 
XXIX) gdje su A3, X1, X2,L1, R1, R3 in definirani kao gore; i kada je LI nitro, navedenu nitro skupinu se reducira u amino skupinu, a dobiveni amino derivat zatim reagira sa spojem formule III G-A4b-L0 (III), gdje
R8, R9, R11, and R12 are each selected from H, an alkyl group, an olefinic group, or an aromatic group; and 
Rs, Ro, Rij 1 R2 su, svaki, odabrani od H, alkil skupine, olefin skupine, aromatske skupine; i
a DNA-targeting RNA comprising: a DNA-targeting segment comprising a nucleotide sequence that is complementary to a sequence in the target DNA, and 
(i) segment koji cilja na DNK 1 koji obuhvaća nukleotidnu sekvencu koja je komplementarna sekvenci u ciljanoj DNK, 1
wherein X and m are as defined above, R1a is hydrogen, alkyl which may be substituted by A, cycloalkyl which may be substituted by A, alkenyl which may be substituted by A, alkynyl which may be substituted by A, aryl or a heterocyclic group which may be substituted by alkyl, and R7 is alkyl, and a compound represented by the formula (V): 
O Ru pri čemu su X i m kao što je definirano gore, R'* je alkil koji može biti supstituiran sa A, cikloalkil koji može biti supstituiran sa A, alkenil koji može biti supstituiran sa A, alkinil koji može biti supstituiran sa A, arilom ili heterocikličkom skupinom, a R/ je alkil, i spoj predstavljen formulom (V):
Optimized poloxamer-HP CD formulations may increase the maximum tolerated dose of imiquimod and improve patient compliance. A pharmaceutical composition comprising imiquimod, lactic acid, a polymer and cyclodextrin, wherein the polymer consists of Poloxamer 407 in an amount of 11% (w/v) to 18% (w/v), and the composition is for bladder instillation. 
Farmaceutski pripravak za upotrebu prema zahtjevu 7 naznačen time da i) barem jedno termoosjetljivo sredstvo je Poloksamer 407 u količini od 10 % (w/v) do 25 % (w/v) ili u količini od 12 % (w/v) do 25 % (w/v), naročito pri čemu je barem jedno termoosjetljivo sredstvo Poloksamer 407 u
The compound of Claim 1, where R6 is hydrogen, fluoro, chloro, or bromo. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je R6 vodik, fluoro, kloro ili bromo.
The solid oral extended release pharmaceutical dosage form of claim 1, wherein the composition comprises 8 mg hydromorphone hydrochloride, and wherein the composition comprises at least about 94 % (by wt) polyethylene oxide. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 1, naznačen time da pripravak sadrži 8 mg hidromorfon hidroklorida, te najmanje oko 94 % (težinski) polietilen oksida.
A method of targeting a molecule, composition or a complex to a site characterized by the presence of an a2B1 integrin ligand, the method comprising attaching or binding the molecule, composition or a complex to the humanized anti-a2 integrin antibody of claim 1 or 3. 
Metoda ciljanja molekule, oblika ili kompleksa prema mjestu naznačenim prisutnošću 2B1 integrin liganda, metoda obuhvaća spajanje ili vezanje molekule, oblika ili kompleksa za humanizirano anti-a2 integrin protutijelo prema zahtjevu 1.